Combination treatment for gastroesophageal junction and esophagogastric cancer

A Phase II Study of Neoadjuvant NAPOX Followed by Chemoradiation With Paclitaxel and Carboplatin in Locally Advanced Esophagogastric Cancer

This study is testing a new combination of liposomal irinotecan with standard treatments to see if it helps people with gastroesophageal junction or esophagogastric cancer feel better.

Quick facts

• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Massachusetts General Hospital (Academic / other)
• Drugs / interventions: chemotherapy, radiation
• Locations: 3 sites (Boston, Massachusetts and 2 other locations)
• Trial ID: NCT04656041 on ClinicalTrials.gov

What this trial studies

This clinical trial investigates the effects of liposomal irinotecan combined with standard treatments such as FOLFOX, carboplatin, paclitaxel, and radiation therapy on patients with gastroesophageal junction or esophagogastric cancer. The study aims to evaluate the safety and effectiveness of this combination therapy in a Phase II setting. Approximately 40 participants will be screened for eligibility and receive treatment, followed by evaluations and follow-up visits to monitor outcomes.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older with confirmed T3/4 or N+ gastroesophageal junction or esophagogastric cancer.

Not a fit: Patients with lower performance status or those who do not meet the specific cancer staging criteria may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could improve survival rates and quality of life for patients with advanced gastroesophageal cancers.

How similar studies have performed: Previous studies have shown promise with similar combination therapies, but this specific approach with liposomal irinotecan is relatively novel.

Eligibility criteria

Inclusion Criteria:

* Participants must meet all the following criteria in order to be eligible to participate in the study:
* Histologically or cytologically confirmed T 3/4 or N+ (\> 1 cm in size or FDG avid) Siewart 1-3 gastroesophageal (GE) junction or esophagogastric cancer. Diagnosis must be confirmed by a DF/HCC institution pathology department prior to registration.
* Age 18 years or older. There will be no upper age restriction.
* ECOG performance status ≤ 1
* Life expectancy of greater than 3 months
* Participants must have adequate organ and marrow function as defined below:

  * absolute neutrophil count ≥ 1,500 cells/mm3
  * platelets ≥ 75,000 cells/mm3
  * total bilirubin ≤ 1.5 x upper limit of normal OR for patients who have undergone biliary stenting, total bilirubin of ≤ 2.0 x upper limit of normal OR two down trending values.
  * AST(SGOT) ≤ 2.5 x upper limit of normal
  * ALT (SGPT) ≤ 2.5 x upper limit of normal
  * creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 30 mL/min/1.73 m2 for participants with creatinine levels above institutional normal.
* The effects of both radiation therapy and the chemotherapy agents used in this trial are known to be teratogenic. Therefore, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation plus 30 days from the last date of study drug administration. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
* Female subject of childbearing potential should have a negative urine or serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG). If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
* Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

* Participants who fulfill any of the following criteria will be excluded from the study:
* Evidence of metastatic disease as determined by chest CT scan, abdomen/pelvis CT scan (or MRI with gadolinium and/or manganese) within six weeks of study entry. Distant nodal disease is allowed if it is in the radiation port.
* Any prior chemotherapy, targeted/biologic therapy, or radiation for treatment of the participant's esophagogastric cancer.
* Treatment of other invasive carcinomas within the last five years with greater than 5% risk of recurrence at time of eligibility screening. Carcinoma in-situ and basal cell carcinoma/ squamous cell carcinoma of the skin are allowed.
* Receipt of any other investigational agents within 4 weeks preceding the start of study treatment.
* Serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator), such as significant cardiac or pulmonary morbidity (e.g.congestive heart failure, symptomatic coronary artery disease and/or cardiac arrhythmias not well controlled with medication) or myocardial infarction within the last 12 months, or ongoing infection as manifested by fever.
* History of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant, precluding informed consent, or interfering with compliance or drug intake.
* Pregnant women are excluded from this study because radiation therapy and the chemotherapy agents to be used have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with these agents, breastfeeding should be discontinued while the mother is receiving protocol therapy.
* Major surgery, excluding laparoscopy, within 4 weeks of the start of study treatment, without complete recovery.
* No concurrent administration of cimetidine (as it can decrease the clearance of 5-FU). Another H2-blocker or proton pump inhibitor may be substituted before study entry.
* Known, existing uncontrolled coagulopathy.
* Prior systemic fluoropyrimidine therapy (unless given in an adjuvant setting and at least six months earlier). Prior topical fluoropyrimidine use is allowed.
* Known hypersensitivity to 5-fluorouracil or known DPD deficiency.
* History of allergic reaction(s) attributed to compounds of similar chemical or biologic composition to 5-fluorouracil, irinotecan, or oxaliplatin.

Where this trial is running

Boston, Massachusetts and 2 other locations

• Massachusetts General Hospital — Boston, Massachusetts, United States (Recruiting)
• Beth-Israel Deaconess Medical Center — Boston, Massachusetts, United States (Not_yet_recruiting)
• Massachusetts General Hospital at Newton Wellesley Hospital — Newton, Massachusetts, United States (Recruiting)

Study contacts

• Principal investigator: Jennifer Wo, MD — Massachusetts General Hospital
• Study coordinator: Jennifer Wo, MD

Conditions Gastroesophageal Junction Adenocarcinoma; Esophagogastric Cancer; Esophagogastric cancer